블록 기반 특징맵 크기 조정을 이용한 DNN 특징맵 압축

윤규리(Curie Yoon),정혜원(Hye Won Jeong),김영웅(Yeongwoong Kim),김연희(Younhee Kim),정세윤(Se-Yoon Jeong),김휘용(Younhee Kim) 한국방송·미디어공학회 2022 한국방송공학회 학술발표대회 논문집 Vol.2022 No.6

자율주행, IoT 등 많은 양의 영상 정보를 실시간으로 처리해야 하는 기술과 mobile device 등의 기기에서 Machine Learning 연산을 하는 소프트웨어들이 등장함에 따라 사람을 위한 영상을 출력하는 영상 부호화 기술 대신 기계의 vision task 성능을 위해 특화된 영상 부호화 기술의 필요성이 대두됐다. 본 연구에서는 영상에서 추출한 특징맵을 Neural-Net based Video Coding 모델을 이용해 압축률과 기계의 vision task 성능을 동시에 최적화한다. 또한, 하드웨어 친화적인 block-based 처리와 이로 인한 성능 저하를 최소화하기 위해 적응적 resizing 방식을 제안한다.

투석치료를 받는 만성신부전 환자의 빈혈에 대한 유전자 재조합 인 에리트로포이에틴(에스포젠)의 임상효과

안규리(Curie Ahn),오하영(Ha Young Oh),박정식(Jung Sik Park),정우경(Woo Kyung Chung),호지숙(Gee Suk Ho),허우성(Woo Sung Huh) 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.2

N/A We conducted a multicenter clinical trial to evaluate the efficacy and safety of recombinant human erythropoietin(Espogen, LG Chemical Ltd.) in the anemic patients of chronic renal failure undergoing dialysis. The patients were end-stage renal disease who were undergoing hemodialysis or peritonea1 dialysis for 3 months or longer and they had less than 8g/dL of hemoglobin and more than 100ng/mL of serum ferritin. Hemodialysis patients were administered 150unit/kg/week of recombinant human erythropoietin as initial dose, and peritoneal dialysis patients 50unitAg, twice per week. We examined hemoglobin value every other week and adjusted the dose in order to maintain hemoglobin level as 10-llg/dL. We enrolled 64 patients and analysed 54 cases in the final. 96.3%(52/54) of patients showed increase by more than 1.0g/dL and the others in- crease by more than 0.5g/dL. Baseline hemoglobin, hematocrit were 7.11±0.85g/dL, 21.3±2.6% and final level were 10.42±1.31g/dL, 31.9±3.5%(p=0.0001), respectively. Reticulocyte was increased after 2 weeks of administration from 0.90±0.74% to 2.45±0.84% The adverse effects included hypertension, headache, increased potassium and phosphate level so required regular monitoring. Therefore we showed that Es-pogen was effective in correcting the anemia of chronic renal failure and didn't have any particular adverse effects.

만성신부전환자의 치료 : 복막투석

안규리 서울대학교 의과대학 내과동문회 1993 含春內科 Vol.24 No.1

신부전 치료의 영양학적 접근

안규리,정우경 대한영양의학회 1999 영양의학 Vol.1 No.3

경련성과 무정위성 뇌성마비아동의 말소리 특성에 관한 연구

이규리 ; 김근조 김천대학교 1993 김천대학교 논문집 Vol.14 No.-

A Study of Spastic and Athetoid Cerebral Palsied Children's Speech Characteristics. This study has experimented spastic and athetoid cerebral palsied children's speech characteristics by distinguishing spoken words into initial, secondary, final consonants. The rate of mispronounced articulation and the error pattern of phonemic manner was exa-mined and the results were as follows. First, rate of error for spastic and athetoid cerebral palsied children's initial, secondary, final consonants was shown as follows: initial secondary final SCPC 9.6% 11.94% 17. 32% ACPC 15. 17 % 20.14% 22. 53% SCPC : spastic cerebral palsied children ACPC : athetoid cerebral palsied children To find the diffrence between the above two groups X? test was applied but there was no significance statistically. (p = .05) Second, error pattern of initial consonants for phonemic manner: In case of spastic cerebral palsied children the order was plosive, fricative, liquids, affricate. The order for athetoid cerebral palsied children was shown as fricative, affricate, plosive, liquids, nasal. To find the difference between the above two groups X? test was applied and there was significance statistically. (X? -4.04, df=1, p<0.05) Third, error pattern of secondary consonants for phonemic manner: In both spastic cerebral palsied children and athetoid cerebral palsied children the order of phonemic error rate was plosive, affricate, fricative, liquids. To find the difference between the above two groups X test was applied but there was no significance statistically. (p. 05)

The Glu/Asp Polymorphism of ecNOS Gene and the Renal Progression in Korean Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients

Lee, Jung Geon,Ahn, Curie,Yoon, Sung-Chul,Park, Jong Hoon,No, Jin Ju,Moon, Chang Suk,Song, Eun Kyeung,Hwang, Yeong Hwan,Hwang, Dae Yeon,Kim, Yon Su,Han, Jin Suk,Kim, Suhnggwon,Lee, Jung Sang,Kim, Seun 한국유전학회 2002 Genes & Genomics Vol.24 No.3

Two genetic loci, PKD1 and PKD2, have been identified as being responsible for ADPKD, but the presence of an intrafamilial clinical diversity suggests that there are disease-modifying loci. We studied the associations between polymorphism in the ecNOS gene, which are known to be associated with chronic tubulointerstitial and vascular changes, and ADPKD progression in Korean patients. A total of 112 individuals who had ADPKD and 41 normal control subjects were genotyped by PCR-RFLP, the Glu298Asp variant of ecNOS gene was discriminated with MboI. The distribution of the alleles for the ecNOS Glu298Asp polymorphism in ADPKD was: G 88 %, T 12 %, which was similar to the result of Korean population (95:5, p = 0.128) but different from Western controls (65:35, p = 0.000). No differences were found between the CRF and the non-CRF groups (p = 1.000) or the early hypertension and the normotension groups (p = 1.000). In conclusion, our results suggest that the polymorphism at Glu298Asp of ecNOS has no association with the renal progression in Korean ADPKD patients.

Mutations of the PKD2 Gene in Korean Patients with Autosomal Dominant Polycystic Kidney Disease

Kyu Beck Lee,Curie Ahn,Un Kyung Kim 한국유전학회 2006 Genes & Genomics Vol.28 No.2

Intestinal parasitic infections in the residents of an emigration camp in Tijuana, Mexico

Sun HUH(허선),Curie AHN(안규리),Jong-Yil CHAI(채종일) 대한기생충학열대의학회 1995 The Korean Journal of Parasitology Vol.33 No.1

복막투석 환자에서 발생한 진균성 복막염의 임상적 특징

오국환,안규리,오윤규,김현리,정우경,김연수,한진석,김진석,김성권,이정상 대한신장학회 2002 Kidney Research and Clinical Practice Vol.21 No.2

목 적: 진균성 복막염은 지속적 외래 복막투석 환자의 이환율과 사망률을 증가시키는 중요한 질환이다. 저자들은 복막투석 환자에서 발생한 진균성 복막염의 원인 진균과 임상상, 치료 방법 및 결과 등을 살펴보고 동일한 기간에 발생한 세균성 복막염의 임상상과 비교 분석함으로써 진균성 복막염의 예방과 치료에 도움을 얻고자 하였다. 방 법: 1991년 1월부터 1999년 12월까지 서울대학교병원에서 복막투석을 시작한 환자 총376명 중 이 기간 동안에 진균성 복막염으로 진단 받은 환자 14명(총 15예)을 후향적으로 분석하였다. 결 과 : 대상 환자들의 평균 연령은 53.7±11.6세(이하 평균±표준편차)이었으며, 남·녀비는12 : 3이었다. 진균성 복막염을 진단 받은 당시까지의 복막투석 기간은 29.2±27.7개월이었다. 원인균은 Candida species가 10예(62.5%)로 가장 많았으며, Aspergillus 2예, Cryptococcus 1예, Penicillium 1예, Torulopsis 1예, Trichosporon beigelii 1예 등이었다. 5예에서 진균과 아울러 세균의 중복 감염이 확인되었다. 발병 당시의 증상은 일반적으로 알려진 세균성 복막염의증상과 유사하였다. 진균성 복막염 환자에서 복막투석 도관은 모두 제거하였으며, amphotericin B, fluconazole, flucytosine 등을 단독 혹은 병합 투여하였다. 질병의 경과 중에 4예(26.7%)에서 장폐색 또는 복막 유착이 합병되었다. 치료 결과로는, 완치 후 도관 재삽입 후 복막 투석을 지속한 경우가 3예(20%), 혈액투석으로 전환한 경우가 9예(60%)이었고, 3예(20%)는 진균성 복막염으로 인하여 사망하였다. 원인 진균이 Candida species인 환자군과 나머지 군에 있어서 사망률에 차이가 있었으나(33.3% vs 0%) 통계적으로 유의하지는 않았다(p=0.11). 투여한 항진균제의 종류에 따른 사망률의 차이는 없었다. 동일한 기간에 발생한 세균성 복막염과 진균성 복막염 환자들의 특성을 비교해 볼 때 도관 제거율과 기술적 실패율은 진균성 복막염에서 유의하게 더 높았다. 결 론 : 진균성 복막염은 드물게 발생하지만 일반적으로 알려진 세균성 복막염의 사망률보다 더 높은 사망률과 복막투석 중단의 원인이 되는 심각한 질환으로서, Candida species가 가장 흔한 원인균이었다. Purpose : Fungal peritonitis is a fatal disease with a high mortality and morbidity to the peritoneal dialysis(PD) patients. This study was implemented to provide a guideline for the prevention and treatment of fungal peritonitis in PD patients by analyzing the clinical and microbiologic features of fungal peritonitis cases. Methods : We analyzed retrospectively into the 15 cases(14 patients) of fungal peritonitis among 376 end stage renal disease(ESRD) patients who newly started PD in the Seoul National University Hospital from Jan. 1991 to Dec. 1999. Results : The patients' age was 53.6±11.6 years (mean±standard deviation) and their male to female ratio was 12:3. They have been on PD for 29.2±27.7 months before the fungal peritonitis developed. Candida species was the most common etiologic agent, accounting for 10(62.5%) out of the 16 fungal organisms isolated from our patients. Among others were two Aspergillus, one Cryptococcus, one Penicillium, one Torulopsis, and one Trichosporon beigelii cases. Bacterial agents were isolated simultaneously in five fungal peritonitis cases. Peritoneal catheters were all removed no later than 72 hours after the diagnosis was made. Patients were given a single or combined therapy with amphotericin B, fluconazole, or flucytosine on the physician's choice. The outcomes of fungal peritonitis were as follows; 20% continued PD, 60% converted to HD and 20% died of fungal peritonitis. We made a comparative analysis between the fungal and bacterial peritonitis cases which developed in the same 5-year period, which showed significantly higher catheter removal and technique failure rates in the fungal cases. Conclusion : Fungal peritonitis is a rare but a fatal disease with a high mortality and a technique failure rate. Candida species was the most prevalent microorganism in our study. (Korean J Nephrol 2002;21(2):303-311)

Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells

Sunam Mander,유동주,박수미,김동휘,용효정,김동식,Curie Ahn,김윤희,성재영,황종익 대한약학회 2018 Archives of Pharmacal Research Vol.41 No.2

Triple-negative breast cancer (TNBC) lacking ofoestrogen receptor, progesterone receptor, and epidermalgrowth factor receptor type 2 is a highly malignant diseasewhich results in a poor prognosis and rare treatmentoptions. Despite the use of conventional chemotherapy forTNBC tumours, resistance and short duration responseslimit the treatment efficacy. Therefore, a need exists todevelop a new chemotherapy for TNBC. The aim of thisstudy was to examine the anti-cancer effects of nafamostatmesilate (NM), a previously known serine protease inhibitorand highly safe drug on breast cancer cells. Here, weshowed that NM significantly inhibits proliferation,migration, and invasion in MDA-MB231 cells, induces G2/M phase cell-cycle arrest, and inhibits the expression ofcyclin-dependent kinase 1 (CDK1). Exposure of MDAMB231cells to NM also resulted in decreased transcriptionfactor activities accompanied by the regulated phosphorylationof signalling molecules and a decrease in metalloproteinases,the principal modulators of the extracellularenvironment during cancer progression. Especially, inhibitionof TGFb-stimulated Smad2 phosphorylation andsubsequent metastasis-related gene expression, and downregulationof ERK activity may be pivotal mechanismsunderlying inhibitory effects of NM on NM inhibits lungmetastasis of breast cancer cells and growth of colonizedtumours in mice. Taken together, our data revealed thatNM inhibits cell growth and metastasis of TNBC cells andindicated that NM is a multi-targeted drug that could be anadjunct therapy for TNBC treatment.